Clinical Studies Sponsored by BioCryst Pharmaceuticals

Clinical Studies where

Trial Sponsor

Name	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
‌ Forodesine in the Treatment of Cutaneous T-Cell Lymphoma	NCT00501735		2007	2011	Interventional
‌ Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia	NCT00095381		2004	2007	Interventional
‌ Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout	NCT00985127	Gout	2009	2010	Interventional
‌ Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)	NCT00289549		2005	2009	Interventional
‌ Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma	NCT00098332	Lymphoma	2004	2011	Interventional
‌ Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens	NCT00419081	Leukemia Lymphoma	2006	2007	Interventional
‌ Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia	NCT00289562		2004	2007	Interventional
‌ Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol	NCT01265264	Arthritis Gout Hyperuricemia	2010	2013	Interventional
‌ BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma	NCT00061880	Lymphoma	2003	2008	Interventional
‌ Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas	NCT00035022	Lymphoma	2001	2004	Interventional
‌ BCX-1777 in Treating Patients With Refractory Cancer	NCT00073944	Cancer	2003		Interventional
‌ A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency	NCT01407874	Arthritis Gout Hyperuricemia	2011	2012	Interventional
‌ Intramuscular Peramivir for the Treatment of Uncomplicated Influenza	NCT00486980	Influenza			Interventional
‌ Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout	NCT01129648	Gout	2010	2010	Interventional
‌ Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)	NCT00640523		2008	2011	Interventional
‌ A Study of Peldesine (BCX-34) in HIV-Infected Patients	NCT00002237				Interventional
‌ Oral Berotralstat Expanded Access Program	NCT04428632	Hereditary angioedema ‌ Hae
‌ First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH	NCT04330534	‌ Paroxysmal nocturnal hemoglobinuria	March 3, 2020	January 25, 2021	Interventional
‌ A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions	NCT03136237	Hereditary angioedema	February 17, 2017	August 15, 2017	Interventional
‌ Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema	NCT03240133		July 31, 2017	January 29, 2019	Interventional
‌ Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema	NCT02670720	Hereditary angioedema ‌ Hae	2015	2016	Interventional
‌ 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks	NCT02303626	Hereditary angioedema ‌ Hae	2014	2016	Interventional
‌ A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza	NCT01224795	Influenza	2010	2010	Interventional
‌ An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates	NCT02819102	Hereditary angioedema	2016	2016	Interventional
‌ A Relative Bioavailability Study of Two Formulations of BCX7353	NCT03202784	Hereditary angioedema	February 27, 2017	September 30, 2017	Interventional

Results per page:

43 results

0 selected

43 results

0 selected